Priothera is developing the orally applied sphingosine 1 phosphate (S1P) receptor modulators for haematological malignancies.
Priothera has raised $2.0M in total funding. The most recent round was Grant. The last funding was announced in June 2025.
Priothera's investors include European Investment Bank, Bpifrance, Earlybird Venture Capital, HealthCap, Fountain Healthcare Partners.
Priothera is headquartered in Dublin, Ireland.
Priothera is developing the orally applied sphingosine 1 phosphate (S1P) receptor modulators for haematological malignancies.
Priothera is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Priothera — Funding & Investors." VCBacked, June 24, 2025, https://www.vcbacked.co/company/priothera. Accessed October 29, 2026.
VCBacked. (2025). Priothera — Funding & Investors. Retrieved October 29, 2026, from https://www.vcbacked.co/company/priothera
{{cite web |title=Priothera — Funding & Investors |url=https://www.vcbacked.co/company/priothera |website=VCBacked |access-date=October 29, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated